Skip Navigation



European Heart Journal Advance Access published online on September 28, 2007
European Heart Journal, doi:10.1093/eurheartj/ehm413
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/21/2561    most recent
ehm413v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tang, W. H. W.
Right arrow Articles by Francis, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tang, W. H. W.
Right arrow Articles by Francis, G. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Exploring new drugs for heart failure: the case of urocortin

W. H. Wilson Tang and Gary S. Francis*

Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA

* Corresponding author. Tel: +1 216 444-3410; fax: +1 216 636-0063. E-mail address: francig@ccf.org

This editorial refers to ‘Urocortin 2 infusion in human heart failure’ by M.E. Davis et al., doi:10.1093/eurheartj/ehm340

The first 10% of the full text of this article appears below.

Over the past decade, clinical development of natriuretic peptide analogues as drug therapy for acute heart failure has sparked a wide range of interests to seek other endogenous vasoactive peptide systems that are operative as adaptive responders in human heart failure. With rapid advances in the molecular understanding of heart failure pathogenesis, several novel neurohormonal systems have been identified and more are under study. Bringing a potential therapeutic concept from bench to bedside today often involves a prerequisite set of animal and human studies. However, much of the attention in recent years has focused on identifying what the best clinical end-points should be or what the sample size should be in order to power statistical significance. Sometimes the fundamental mechanisms . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Urocortin 2 infusion in human heart failure
Mark E. Davis, Christopher J. Pemberton, Timothy G. Yandle, Steve F. Fisher, John G. Lainchbury, Christopher M. Frampton, Miriam T. Rademaker, and Mark Richards
EHJ 2007 28: 2589-2597. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 ESC Textbook of Cardiovascular MedicineHome page
J. McMurray, M. Petrie, K. Swedberg, M. Komajda, S. Anker, and R. Gardner
CHAPTER 23 Heart Failure
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]